Creative imitation in late industrializing countries: the case of biopharmaceutics in South Korea and India

Bibliography

• Abrol, D., P. Prajapati, and N. Singh. 2011. “Globalization of the Indian Pharmaceutical Industry: Implications for Innovation.” International Journal of Institutions and Economies 3 (2): 327–365.
   Google Scholar
• Abrol, D., T. Sundararaman, H. Madhavan, and K. J. Joseph. 2016. “Building Inclusive Health Innovation Systems: Lessons from India.” Cadernos de Saúde Pública 32 (s2), Available at: 16. doi:10.1590/0102-311X00045215.
   Google Scholar
• Berkowitz, S., J. Engen, J. Mazzeo, and G. Jones. 2012. “Analytical Tools for Characterizing Biopharmaceuticals and the Implications for Biosimilars.” Nature Reviews Drug Discovery 11 (7): 527–540. doi:10.1038/nrd3746.
   PubMed Web of Science ®Google Scholar
• BioPlan. 2015. “12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.” BioPlan Associates, ISBN 978-1-934106-36-5.
   Google Scholar
• Chaturvedi, Sachin. 2007. India Innovation Systems and Emergence of Biopharmaceutical Sector: Issues and Prospects. Research and Information System for Development Countries (RIS). RIS Discussion Papers #124. New Dehli, India. http://ris.org.in/images/RIS_images/pdf/dp124_pap.pdf.
   Google Scholar
• Chowdhury, P. R. 2011. Outsourcing Biopharma R&D to India. Great Britain: Biohealthcare Publishing. Ltd. Oxford.
   Google Scholar
• Chung, S. 2014. “Shaping the Biosimilars Opportunity” IMS Consulting group, presentation at Biologics World Taiwan/February 2014.
   Google Scholar
• Department of Biotechnology. 2015. National Biotechnology Development Strategy 2015-2020. New Delhi: Department of Biotechnology, Ministry of Science & Technology, Government of India.
   Google Scholar
• Dranitsaris, G., I. Jacobs, C. Kirchhoff, R. Popovian, and L. G. Shane. 2017. “Drug Tendering: Drug Supply and Shortage Implications for the Uptake of Biosimilars.” ClinicoEconomics and Outcomes Research: CEOR 9: 573–584. doi:10.2147/CEOR.S140063.
   PubMed Web of Science ®Google Scholar
• Freeman, C. 2002. “Continental, National and Sub-National Innovation Systems—Complementarity and Economic Growth.” Research Policy 31: 191–211. doi:10.1016/S0048-7333(01)00136-6.
   Web of Science ®Google Scholar
• Gerschenkron, A. 1962. Economic Backwardness in Historical Perspective: A Book of Essays (No. 330.947 G381). Cambridge, MA: Belknap Press of Harvard University Press.
   Google Scholar
• Guennif, S., and S. V. Ramani. 2012. “Explaining Divergence in Catching-up in Pharma Between India and Brazil Using the NSI Framework.” Research Policy 41 (2): 430–441.
   Web of Science ®Google Scholar
• Gutman, G., and P. Lavarello. 2015. “Early Imitators in the Context of the New Technological Paradigm: The (incipient) Experience of Argentina’s Biopharmaceutical Industry.” In 13th GLOBELICS International Conference; 23–25 November 2015, Havana.
   Google Scholar
• Hikino, T., A. H. Amsden, and L. Wolfson. 1995. “La industrialización tardía en perspectiva histórica.” Desarrollo Económico 35 (137): 3–34. doi:10.2307/3467421.
   Google Scholar
• Hirschman, A. 1980. “Auge y ocaso de la teoría económica del desarrollo.” El Trimestre Económico 47 (188(4): 1055–1077.
   Google Scholar
• Hwang, S. W. 2015. “Latecomers’ Science-Based Catch-up in Transition: The Case of the South Korean Pharmaceutical Industry.” (Ph.D. Doctoral thesis). University of Sussex.
   Google Scholar
• Hwang, S. W. 2017. “Middle-ground Players in Dynamic Imitative Markets: Global Entry Strategies of South Korean Firms in the Biosimilars Market.” Technology Analysis & Strategic Management 29 (3): 325–338. doi:10.1080/09537325.2016.1243660.
   Web of Science ®Google Scholar
• IBEF. 2011. Formula of Success. Emerging trends in Biosimilars in India. India Brand Equity Foundation (IBEF). Available at: http://www.ibef.org/download/Biosimilars-in-India-30312.pdf.
   Google Scholar
• IMS HEALTH. 2014. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape.
   Google Scholar
• Johann, D. 2013. The Reconfiguration of a Latecomer Innovation System: Governing Pharmaceutical Biotechnology Innovation in South South Korea. Frankfurt am Main: Peter Lang.
   Google Scholar
• Joseph, R. K. 2009. India's Trade in Drugs and Pharmaceuticals: Emerging Trends, Opportunities and Challenges. New Delhi: Research and Information System for Developing Countries.
   Google Scholar
• Joseph, R. K. 2012. “Policy Reforms in the Indian Pharmaceutical Sector Since 1994: Impact on Exports and Imports.” Economic and Political Weekly 47: 62–72.
   Google Scholar
• Kale, Dinar. 2019. “From Small Molecule Generics to Biosimilars: Technological Upgrading and Patterns of Distinctive Learning Processes in the Indian Pharmaceutical Industry.” Technological Forecasting & Social Change 145 (2019): 370–383.
   Google Scholar
• Kale, D., and F. Huzair. 2015. Evaluation of creative imitation under the TRIPS compliant patent regime: Development of biosimilar capabilities in the Indian pharmaceutical sector. Paper Presented at the Atlanta Conference on Science and Innovation Policy, 17-19 September 2015, Atlanta, GA.
   Google Scholar
• Kedron, Peter, and Sharmistha Bagchi-Sen. 2012. “Foreign Direct Investment in Europe by Multinational Pharmaceutical Companies from India.” Journal of Economic Geography 12: 809–839.
   Web of Science ®Google Scholar
• Kim, L. 1997. Imitation to Innovation: The Dynamics of South Korea’s Technological Learning. Boston: Harvard Business Press.
   Google Scholar
• KRIBB (web page) South Korean Research Institute of Bioscience and Biotechnology, www.kribb.re.kr
   Google Scholar
• Lee, K. 2005. “Making a Technological Catch-up: Barriers and Opportunities.” Asian Journal of Technology Innovation 13 (2): 97–131.
   Google Scholar
• Lee, K., and C. Lim. 2001. “Technological Regimes, Catching-up and Leapfrogging: Findings from the South Korean Industries.” Research Policy 30 (3): 459–483.
   Web of Science ®Google Scholar
• Lee, K., and F. Malerba. 2017. “Catch-up Cycles and Changes in Industrial Leadership: Windows of Opportunity and Responses of Firms and Countries in the Evolution of Sectoral Systems.” Research Policy 46 (2): 338–351.
   Web of Science ®Google Scholar
• Moorkens, E., A. G. Vulto, and I. Huys. 2020. “An Overview of Patents on Therapeutic Monoclonal Antibodies in Europe: Are They a Hurdle to Biosimilar Market Entry?” MAbs 12 (1): 1743517. doi:10.1080/19420862.2020.1743517.
   PubMed Web of Science ®Google Scholar
• Mroczkowski, Tomasz. 2012. The New Players in Life Science Innovation: Best Practices in R&D from Around the World. Upper Saddle River, New Jersey, United States: Financial Times Press.
   Google Scholar
• Mueller, Lisa, and Nidhi Anand. 2014. An Overview of Biosimilars and the Biosimilar Pathway in India. Bric Wall Blog. https://bricwallblog.wordpress.com/2014/05/21/an-overview-of-biosimilars-and-the-biosimilar-pathway-in-india/.
   Google Scholar
• Niosi, J. 2017. “Imitation and Innovation New Biologics, Biosimilars and Biobetters.” Technology Analysis & Strategic Management 29 (3): 251–262.
   Web of Science ®Google Scholar
• Niosi, J., P. Hanel, and S. Reid. 2012. “The International Diffusion of Biotechnology: The Arrival of Developing Countries.” Journal of Evolutionary Economics 22 (4): 767–783. doi:10.1007/s00191-012-0284-2.
   Web of Science ®Google Scholar
• Niosi, J., S. Reid, and J. Zhao. 2013. “The Internationalization of Chinese and Indian Pharmaceutical Companies.” GLOBELICS CONFERENCE, 2013- Ankara – Turquía.
   Google Scholar
• Ortiz-Prado, E., J. Ponce-Zea, J. E. Vasconez, D. Castillo, D. C. Checa-Jaramilloz, N. Rodríguez-Burneo, and C. Galarza-Maldonado. 2020. “Current Trends for Biosimilars in the Latin American Market.” Generics and Biosimilars Initiative Journal 9 (2): 64–74.
   Google Scholar
• Pérez, C. 2001. “Cambio tecnológico y oportunidades de desarrollo como blanco móvil.” Revista de la Cepal 75 (December): 115–136.
   Google Scholar
• Perez, C., and Luc Soete. 1988. “Catching up in Technology: Entry Barriers and Windows of Opportunity.” In Technical Change and Economic Theory, edited by Giovanni Dosi, Christopher Freeman, Richard Nelson, Gerald Silverberg, and Luc Soete, 458–479. London: Francis Printer.
   Google Scholar
• Pisano, G. P. 2006. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business Press.
   Google Scholar
• Pisano, G. P., and W. C. Shih. 2012. “Does America Really Need Manufacturing.” Harvard Business Review 90 (3): 94–102.
   PubMed Web of Science ®Google Scholar
• Reuters. 2015. India risks missing boat as biosimilars shake up drug industry. October 15. http://www.reuters.com/article/us-india-biosimilars-idUSKCN0S82OQ20151014.
   Google Scholar
• Scott Morton, F. M., A. D. Stern, and S. Stern. 2018. “The Impact of the Entry of Biosimilars: Evidence from Europe.” Review of Industrial Organization 53 (1): 173–210. doi:10.1007/s11151-018-9630-3.
   Web of Science ®Google Scholar
• Srinivas, S. 2006. “Industrial Development and Innovation: Some Lessons from Vaccine Procurement.” World Development 34 (10): 1742–1764.
   Web of Science ®Google Scholar
• Sztulwark, S. 2019. “The Center and the Periphery in the Structural Logic of the New Capitalism.” In Development in Latin America. Critical Discussions from the Periphery, edited by V. R. Fernández, and G. Brondino, 47–67. Cham: Plagrave/Macmillan.
   Google Scholar
• Thorsteinsdóttir, H., U. Quach, A. S. Daar, and P. Singer. 2014. “Conclusions: Promoting Biotechnology Innovation in Developing Countries.” Nature Biotechnology 22. doi:10.1038/nbt1204supp-DC48.
   Google Scholar
• Wechsler, J. 2011. “Biosimilars Development Raises Research Questions.” Applied Clinical Trials 20 (7): 20.
   Google Scholar
• Wong, J. 2004. “From Learning to Creating: Biotechnology and the Postindustrial Developmental State in South Korea.” Journal of East Asian Studies 4 (3): 491–517.
   Google Scholar
• Yin, R. K. 2017. Case Study Research and Applications: Design and Methods. London: Sage publications.
   Google Scholar
• Zhang, M. Y., J. Li, H. Hu, and Y. T. Wang. 2015. “Seizing the Strategic Opportunities of Emerging Technologies by Building up Innovation System: Monoclonal Antibody Development in China.” Health Research Policy and Systems 13 (1): 64.
   PubMedGoogle Scholar